|
Change Bisphosphonate Labeling, Agency Panel Recommends
A joint FDA advisory committee voted 17–6 Sept. 9 to recommend labeling changes clarifying the recommended length of bisphosphonate use for osteoporosis patients.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives